Brind.

Esperion Therapeutics licensed products to HLS Therapeutics Inc. for commercialization in the Canadian market.

1 report, 1 independent Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Esperion Therapeutics licensed products to HLS Therapeutics Inc. for commercialization in the Canadian market.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • CNW GroupHLS Therapeutics Announces Q2 2025 Financial Results Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-date Made principal repayments on the Com